Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR245409 + bendamustine + rituximab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
SAR245409 + bendamustine + rituximab is a combination therapy studied for the treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). SAR245409 is a dual inhibitor of the PI3K/mTOR pathway, bendamustine is an alkylating agent, and rituximab is a monoclonal antibody targeting CD20 on B cells. The regimen aims to improve antitumor activity via multiple mechanisms: inhibition of cell growth and survival pathways (PI3K/mTOR), direct DNA damage (alkylation), and immune-mediated destruction of malignant B cells (CD20 targeting). This combination was investigated in a phase 1b dose-escalation clinical trial to establish safety, tolerability, recommended phase 2 dosing, and preliminary efficacy[1][3].
- Other names
- SAR245409 + bendamustine + rituximab
02
Targets
DNAMechanistic target of rapamycin kinase complex 2CD20 (B-lymphocyte antigen CD20)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on SAR245409 + bendamustine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR245409 + bendamustine + rituximab.